Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty
- Registration Number
- NCT02568735
- Lead Sponsor
- Kuopio University Hospital
- Brief Summary
The main purpose of this study was to determine the plasma and central nervious system pharmacokinetics of dexketoprofen and etoricoxib. The secondary aim was to asses their effect on the concentrations of interleukin 6, prostaglandin E2 and other proinflammatory markers both in plasma and cerebrospinal fluid. Thirdly, the investigators aimed to evaluate their efficacy in postoperative pain treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- agreed to participate the study
- American Society of Anesthesiologist s physical status classification 1-3
- elective hip arthroplasty planned
- no contraindications to the study drugs
- no contraindication to lumbar puncture
Exclusion Criteria
- refused to participate the study
- age less than 40 or over 75 years
- Planned anesthesia method other than spinal anesthesia
- contraindications to the study drugs
- Contraindications to lumbar puncture
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dexketoprofen Dexketoprofen Dexketoprofen 0,5 mg/kg up to 50 mg intravenously Etoricoxib Etoricoxib Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight\> 90kg by mouth
- Primary Outcome Measures
Name Time Method Cerebrospinal fluid concentration dexketoprofen and etoricoxib 0-24 hours Cerebrospinal fluid concentration of dexketoprofen and etoricoxib
Plasma concentration dexketoprofen and etoricoxib 0-24 hours Plasma concentration dexketoprofen and etoricoxib
- Secondary Outcome Measures
Name Time Method Pain 0-24 h Pain assessed with numeral rating scale